Global Information
회사소개 | 문의

피부 편평세포암(cSCC) : 시장 인사이트, 역학, 시장 예측(-2027년)

Cutaneous Squamous cell Carcinoma (CsCC) - Market Insight, Epidemiology and Market Forecast - 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 01월 상품 코드 524523
페이지 정보 영문 100 Pages
가격
US $ 6,250 ₩ 7,102,000 PDF by E-mail (Single User License)
US $ 12,500 ₩ 14,205,000 PDF by E-mail (Site License)
US $ 18,750 ₩ 21,307,000 PDF by E-mail (Global License)


피부 편평세포암(cSCC) : 시장 인사이트, 역학, 시장 예측(-2027년) Cutaneous Squamous cell Carcinoma (CsCC) - Market Insight, Epidemiology and Market Forecast - 2028
발행일 : 2019년 01월 페이지 정보 : 영문 100 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 피부 편평세포암(cSCC: Cutaneous Squamous Cell Carcinoma) 시장에 대해 조사했으며, 질병 개요, 현행 치료법, 출시된 치료제 및 신약 프로파일, 주요 7개국 시장 동향, 역학적 예측, 미충족 요구, 치료제별 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인 등의 정보를 정리했습니다.

목차

제1장 보고서 개요

제2장 피부 편평세포암(cSCC) 시장 개요

  • 주요 7개국 시장 규모(실적)
  • 주요 7개국 시장 규모(예측)

제3장 질환 배경과 개요 : 피부 편평세포암(cSCC)

  • 서론
  • 원인
  • 병태생리
  • 증상
  • 위험인자
  • 진단

제4장 역학과 환자 인구

  • 주요 7개국의 이환율(실적, 예측)
  • 주요 7개국의 이환율 : 연령층별(실적, 예측)
  • 주요 7개국의 이환율 : 성별(실적, 예측)
  • 주요 7개국의 이환율 : 병기별(실적, 예측)
  • 주요 7개국의 진단수, 치료 가능한 증례수(실적, 예측)

제5장 피부 편평세포암(cSCC) : 국가별 역학

  • 미국
    • 이환율(실적, 예측)
    • 이환율 : 연령층별(실적, 예측)
    • 이환율 : 성별(실적, 예측)
    • 이환율 : 병기별(실적, 예측)
    • 진단수, 치료 가능한 증례수(실적, 예측)
  • EU 5개국
    • 독일
      • 이환율(실적, 예측)
      • 이환율 : 연령층별(실적, 예측)
      • 이환율 : 성별(실적, 예측)
      • 이환율 : 병기별(실적, 예측)
      • 진단수, 치료 가능한 증례수(실적, 예측)
    • 프랑스
      • 이환율(실적, 예측)
      • 이환율 : 연령층별(실적, 예측)
      • 이환율 : 성별(실적, 예측)
      • 이환율 : 병기별(실적, 예측)
      • 진단수, 치료 가능한 증례수(실적, 예측)
    • 이탈리아
      • 이환율(실적, 예측)
      • 이환율 : 연령층별(실적, 예측)
      • 이환율 : 성별(실적, 예측)
      • 이환율 : 병기별(실적, 예측)
      • 진단수, 치료 가능한 증례수(실적, 예측)
    • 스페인
      • 이환율(실적, 예측)
      • 이환율 : 연령층별(실적, 예측)
      • 이환율 : 성별(실적, 예측)
      • 이환율 : 병기별(실적, 예측)
      • 진단수, 치료 가능한 증례수(실적, 예측)
    • 영국
      • 이환율(실적, 예측)
      • 이환율 : 연령층별(실적, 예측)
      • 이환율 : 성별(실적, 예측)
      • 이환율 : 병기별(실적, 예측)
      • 진단수, 치료 가능한 증례수(실적, 예측)
  • 일본
    • 이환율(실적, 예측)
    • 이환율 : 연령층별(실적, 예측)
    • 이환율 : 성별(실적, 예측)
    • 이환율 : 병기별(실적, 예측)
    • 진단수, 치료 가능한 증례수(실적, 예측)

제6장 현행 치료법

  • 치료 알고리즘
  • 치료 가이드라인

제7장 출시된 치료제

  • Cemiplimab : Regeneron Pharmaceuticals
  • 작용기전
  • 규제 마일스톤
  • 장단점
  • 안전성과 유효성
  • 제품 개요

제8장 리포트를 참조

제9장 신약

  • 주요 교차 경쟁
    • Talimogene laherparepvec : Amgen
    • 규제 마일스톤
    • 임상 개발
    • 제품 개요
    • 임상 파이프라인
    • Pembrolizumab : Merck Sharp&Dohme

제10장 보고서를 참조

제11장 피부 편평세포암(cSCC) 시장 규모

  • 주요 소견
  • 주요 7개국 시장 분석

제12장 주요 7개국 시장 분석 : 국가별

  • 미국
    • 시장 규모
    • 시장 규모 : 치료제별
  • 독일
  • 프랑스
  • 영국
  • 스페인
  • 이탈리아
  • 일본

제13장 시장 성장 촉진요인

제14장 시장 성장 저해요인

제15장 조사 방법

  • 이용한 정보 출처

제16장 DelveInsight의 서비스 내용

제17장 면책사항

제18장 DelveInsight에 대해

LSH 18.12.10

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Table 7: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Table 12: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Table 16: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Table 17: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Table 22: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Table 27: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Table 32: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Table 37: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 42:7MM- Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 45: United States-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 48: Germany-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 51: France-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 54: Italy-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 57: Spain-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 60:UK-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Table 63: Japan-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Figure 7: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Figure 17: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Figure 32: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC) in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 45: United States-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 51: France-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 60:UK-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Therapies in USD MM (2016-2028)

DelveInsight's "Cutaneous Squamous cell Carcinoma (CsCC) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Cutaneous Squamous cell Carcinoma (CsCC) epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Cutaneous Squamous cell Carcinoma (CsCC) Understanding and Treatment Algorithm

The market report provides the overview of the Cutaneous Squamous cell Carcinoma (CsCC) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Cutaneous Squamous cell Carcinoma (CsCC) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Cutaneous Squamous cell Carcinoma (CsCC) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Cutaneous Squamous cell Carcinoma (CsCC) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Cutaneous Squamous cell Carcinoma (CsCC) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Cutaneous Squamous cell Carcinoma (CsCC) market.

Cutaneous Squamous cell Carcinoma (CsCC) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Cutaneous Squamous cell Carcinoma (CsCC) Report Insights

  • Patient Population in Cutaneous Squamous cell Carcinoma (CsCC)
  • Therapeutic Approaches in Cutaneous Squamous cell Carcinoma (CsCC)
  • Cutaneous Squamous cell Carcinoma (CsCC) Pipeline Analysis
  • Cutaneous Squamous cell Carcinoma (CsCC) Market Size and Trends
  • Cutaneous Squamous cell Carcinoma (CsCC) Market Opportunities
  • Impact of upcoming Therapies in Cutaneous Squamous cell Carcinoma (CsCC)

Cutaneous Squamous cell Carcinoma (CsCC) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Cutaneous Squamous cell Carcinoma (CsCC) Report Assessment

  • Current Treatment Practices in Cutaneous Squamous cell Carcinoma (CsCC)
  • Unmet Needs in Cutaneous Squamous cell Carcinoma (CsCC)
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous Squamous cell Carcinoma (CsCC) market
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous Squamous cell Carcinoma (CsCC) market
  • To understand the future market competition in the Cutaneous Squamous cell Carcinoma (CsCC) market.

Table of Contents

1. Report Introduction

2. Cutaneous Squamous cell Carcinoma (CsCC) Market Overview at a Glance

  • 2.1. Market Share Distribution of Cutaneous Squamous cell Carcinoma (CsCC) in 2016
  • 2.2. Market Share Distribution of Cutaneous Squamous cell Carcinoma (CsCC) in 2028

3. Disease Background and Overview: Cutaneous Squamous cell Carcinoma (CsCC)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Cutaneous Squamous cell Carcinoma (CsCC) in 7MM
  • 4.3. Total Prevalent Patient Population of Cutaneous Squamous cell Carcinoma (CsCC) in 7MM - By Countries

5. Epidemiology of Cutaneous Squamous cell Carcinoma (CsCC) by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.1.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.1.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.1.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.1.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.4.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.4.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.4.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.4.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.5.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.5.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.5.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.5.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.6.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.6.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.6.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.6.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.7.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.7.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.7.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.7.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.8.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.8.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.8.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.8.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.9.3. Sub-Type Specific cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.9.4. Sex- Specific Cases of the Cutaneous Squamous cell Carcinoma (CsCC) *
    • 5.9.5. Diagnosed Cases of the Cutaneous Squamous cell Carcinoma (CsCC)
    • 5.9.6. Treatable Cases of the Cutaneous Squamous cell Carcinoma (CsCC)

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Cutaneous Squamous cell Carcinoma (CsCC)

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Cutaneous Squamous cell Carcinoma (CsCC)

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Cutaneous Squamous cell Carcinoma (CsCC) : 7MM Market Analysis

  • 12.1. 7MM Market Size of Cutaneous Squamous cell Carcinoma (CsCC)
  • 12.2. 7MM Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC)
  • 12.3. 7MM Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products

13. Cutaneous Squamous cell Carcinoma (CsCC) : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in United States
    • 13.1.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in United States
    • 13.1.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Germany
      • 13.2.1.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in France
      • 13.2.2.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in France
      • 13.2.2.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Italy
      • 13.2.3.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Spain
      • 13.2.4.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in United Kingdom
      • 13.2.5.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Cutaneous Squamous cell Carcinoma (CsCC) in Japan
    • 13.3.2. Percentage Share of drugs marketed for Cutaneous Squamous cell Carcinoma (CsCC) in Japan
    • 13.3.3. Market Sales of Cutaneous Squamous cell Carcinoma (CsCC) by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

Back to Top
전화 문의
이용안내
 
BCC Research